Age- and sex- differences in efficacy of treatments for type 2 diabetes: Network meta-analysis of aggregate and individual level data
SGLT2 inhibitors are effective in lowering HbA1c and reducing cardiovascular risks, with efficacy varying by age, but age alone should not preclude treatment.
Where it sits
this study against the rest of the albiglutide corpusSummary and findings
This study assessed the efficacy of SGLT2 inhibitors, GLP1 receptor analogues, and DPP4 inhibitors in adults with type 2 diabetes, focusing on age and sex differences. A total of 616 trials were identified, with individual participant data obtained for 75 trials. The findings indicated that SGLT2 inhibitors reduced HbA1c by 0.5-1.0% overall compared to placebo, with variations in efficacy based on age.
Abstract
<h4>Importance</h4> Sodium glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor analogues (GLP1ra) and dipeptidyl peptidase-4 inhibitors (DPP4i) improve hyperglycaemia and, in the case of SGLT2i and GLP1ra, reduce the risk of major adverse cardiovascular events (MACE) in type 2 diabetes. It is not clear whether efficacy varies by age or sex. <h4>Objective</h4> Assess whether age or sex are associated with differences in efficacy of SGL2i, GLP1ra and DPP4i. <h4>Data sources</h4> Medline, Embase and clinical trial registries. <h4>Study selection</h4> Two independent reviewers screened for randomised controlled trials of SGLT2i/GLP1ra/DPP4i, compared to placebo/active comparator, in adults with type 2 diabetes. <h4>Data extraction and synthesis</h4> We sought individual participant data (IPD) all eligible studies. Where IPD were available, we modelled age- and sex-treatment interactions for each trial. Otherwise, we assessed age- sex distributions along with results from aggregate trial data. IPD and aggregate findings were combined in a Bayesian network meta-analysis. <h4>Main outcome measures</h4> HbA1c and MACE. <h4>Results</h4> We identified 616 eligible trials (604 reporting HbA1c, 23 reporting MACE) and obtained IPD for 75 trials (6 reporting MACE). Mean age was 59.0 (10.7) years and 64.0 (8.6) in HbA1c and MACE trials, respectively. Proportions of female were 43.1% and 44.0% in HbA1c and MACE trials, respectively. SGLT2i reduced HbA1c by 0.5-1.0% overall compared to placebo. This reduction versus placebo was attenuated in older participants (change in HbA1c 0.25 percentage-points less for 75-year-olds compared to 45-year-olds). SGLT2i showed greater relative efficacy in MACE risk reduction among older than younger people. This finding was sensitive to the exclusion of one of the IPD MACE trials, however, in all sensitivity analyses, SGLT2i were either as efficacious or more efficacious in older participants. There was no consistently significant difference in efficacy by age for GLP1ra or DPP4i for HbA1c or MACE, nor were there consistent significant sex differences for any class. <h4>Conclusion</h4> Newer glucose-lowering drugs are efficacious across age and sex groups. SGLT2i are more cardioprotective in older than younger people despite smaller HbA1c reductions. Age alone should not be a barrier to treatments with proven cardiovascular benefit providing they are well tolerated align with patient priorities.